Antiobesity functional leads and targets for drug development

Gabriel O. Anyanwu; Andreas F. Kolb; Giovanna Bermano

doi:10.1016/B978-0-12-817890-4.00009-3

Antiobesity functional leads and targets for drug development

Gabriel O. Anyanwu^*, Andreas F. Kolb, Giovanna Bermano

^*Corresponding author for this work

The Rowett Institute of Nutrition and Health

Research output: Chapter in Book/Report/Conference proceeding › Chapter

7 Citations (Scopus)

Abstract

Obesity is the abnormal accumulation of fat in the body. It is an increasing global health challenge with health, social, and economic costs. Health risks associated with obesity include diabetes, hypertension, cardiovascular diseases, stroke, osteoarthritis, sleep apnea, and some types of cancer. The treatment/management of obesity has involved the use of dietary intervention alongside a few synthetic drugs, currently on the market, which is reported to have unpleasant side effects. For this reason, it is paramount to search for antiobesity drugs from synthetic and natural sources aimed at existing and/or new therapeutic targets. This chapter highlights a number of antiobesity lead compounds discovered from various classes of phytochemicals acting on identified therapeutic targets, which have been evaluated through preclinical and clinical studies in an attempt to develop them into antiobesity drugs, although most of them are yet to make it into the commercial market.

Original language	English
Title of host publication	Phytochemicals as Lead Compounds for New Drug Discovery
Editors	Chukwuebuka Egbuna, Shashank Kumar, Jonathan Ifemeje, Shahira Ezzat, Saravanan Kaliyaperumal
Place of Publication	Amsterdam
Publisher	Elsevier
Chapter	9
Pages	143-160
Number of pages	18
ISBN (Electronic)	9780128178911
ISBN (Print)	9780128178904
DOIs	https://doi.org/10.1016/B978-0-12-817890-4.00009-3
Publication status	Published - 2020

Bibliographical note

Funding Information:
Dr. Gabriel Anyanwu is funded by Bingham University. Work in the laboratory of Dr. Giovanna Bermano is funded by national charities, Biotechnology and Biological Sciences Research Council (BBSRC) and Robert Gordon University. While work in the laboratory of Dr. Andreas Kolb is funded by The Scottish Government Rural and Environment Science and Analytical Services Division (RESAS), the BBSRC and the Genomia Fund.

Publisher Copyright:
© 2020 Elsevier Inc. All rights reserved.

Keywords

Adipocyte
Adipogenesis
Body mass index
Drug
Lead compound
Lipase
Obesity
Phytochemical
Target
Thermogenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-817890-4.00009-3

Cite this

Antiobesity functional leads and targets for drug development. / Anyanwu, Gabriel O.; Kolb, Andreas F.; Bermano, Giovanna.
Phytochemicals as Lead Compounds for New Drug Discovery. ed. / Chukwuebuka Egbuna; Shashank Kumar; Jonathan Ifemeje; Shahira Ezzat; Saravanan Kaliyaperumal. Amsterdam: Elsevier, 2020. p. 143-160.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

@inbook{8edeee7603fc4442814d3d9069371bac,

title = "Antiobesity functional leads and targets for drug development",

abstract = "Obesity is the abnormal accumulation of fat in the body. It is an increasing global health challenge with health, social, and economic costs. Health risks associated with obesity include diabetes, hypertension, cardiovascular diseases, stroke, osteoarthritis, sleep apnea, and some types of cancer. The treatment/management of obesity has involved the use of dietary intervention alongside a few synthetic drugs, currently on the market, which is reported to have unpleasant side effects. For this reason, it is paramount to search for antiobesity drugs from synthetic and natural sources aimed at existing and/or new therapeutic targets. This chapter highlights a number of antiobesity lead compounds discovered from various classes of phytochemicals acting on identified therapeutic targets, which have been evaluated through preclinical and clinical studies in an attempt to develop them into antiobesity drugs, although most of them are yet to make it into the commercial market.",

keywords = "Adipocyte, Adipogenesis, Body mass index, Drug, Lead compound, Lipase, Obesity, Phytochemical, Target, Thermogenesis",

author = "Anyanwu, {Gabriel O.} and Kolb, {Andreas F.} and Giovanna Bermano",

note = "Funding Information: Dr. Gabriel Anyanwu is funded by Bingham University. Work in the laboratory of Dr. Giovanna Bermano is funded by national charities, Biotechnology and Biological Sciences Research Council (BBSRC) and Robert Gordon University. While work in the laboratory of Dr. Andreas Kolb is funded by The Scottish Government Rural and Environment Science and Analytical Services Division (RESAS), the BBSRC and the Genomia Fund. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc. All rights reserved.",

year = "2020",

doi = "10.1016/B978-0-12-817890-4.00009-3",

language = "English",

isbn = "9780128178904",

pages = "143--160",

editor = "Chukwuebuka Egbuna and Shashank Kumar and Jonathan Ifemeje and Shahira Ezzat and Saravanan Kaliyaperumal",

booktitle = "Phytochemicals as Lead Compounds for New Drug Discovery",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Antiobesity functional leads and targets for drug development

AU - Anyanwu, Gabriel O.

AU - Kolb, Andreas F.

AU - Bermano, Giovanna

N1 - Funding Information: Dr. Gabriel Anyanwu is funded by Bingham University. Work in the laboratory of Dr. Giovanna Bermano is funded by national charities, Biotechnology and Biological Sciences Research Council (BBSRC) and Robert Gordon University. While work in the laboratory of Dr. Andreas Kolb is funded by The Scottish Government Rural and Environment Science and Analytical Services Division (RESAS), the BBSRC and the Genomia Fund. Publisher Copyright: © 2020 Elsevier Inc. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Obesity is the abnormal accumulation of fat in the body. It is an increasing global health challenge with health, social, and economic costs. Health risks associated with obesity include diabetes, hypertension, cardiovascular diseases, stroke, osteoarthritis, sleep apnea, and some types of cancer. The treatment/management of obesity has involved the use of dietary intervention alongside a few synthetic drugs, currently on the market, which is reported to have unpleasant side effects. For this reason, it is paramount to search for antiobesity drugs from synthetic and natural sources aimed at existing and/or new therapeutic targets. This chapter highlights a number of antiobesity lead compounds discovered from various classes of phytochemicals acting on identified therapeutic targets, which have been evaluated through preclinical and clinical studies in an attempt to develop them into antiobesity drugs, although most of them are yet to make it into the commercial market.

AB - Obesity is the abnormal accumulation of fat in the body. It is an increasing global health challenge with health, social, and economic costs. Health risks associated with obesity include diabetes, hypertension, cardiovascular diseases, stroke, osteoarthritis, sleep apnea, and some types of cancer. The treatment/management of obesity has involved the use of dietary intervention alongside a few synthetic drugs, currently on the market, which is reported to have unpleasant side effects. For this reason, it is paramount to search for antiobesity drugs from synthetic and natural sources aimed at existing and/or new therapeutic targets. This chapter highlights a number of antiobesity lead compounds discovered from various classes of phytochemicals acting on identified therapeutic targets, which have been evaluated through preclinical and clinical studies in an attempt to develop them into antiobesity drugs, although most of them are yet to make it into the commercial market.

KW - Adipocyte

KW - Adipogenesis

KW - Body mass index

KW - Drug

KW - Lead compound

KW - Lipase

KW - Obesity

KW - Phytochemical

KW - Target

KW - Thermogenesis

UR - http://www.scopus.com/inward/record.url?scp=85092669387&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-817890-4.00009-3

DO - 10.1016/B978-0-12-817890-4.00009-3

M3 - Chapter

AN - SCOPUS:85092669387

SN - 9780128178904

SP - 143

EP - 160

BT - Phytochemicals as Lead Compounds for New Drug Discovery

A2 - Egbuna, Chukwuebuka

A2 - Kumar, Shashank

A2 - Ifemeje, Jonathan

A2 - Ezzat, Shahira

A2 - Kaliyaperumal, Saravanan

PB - Elsevier

CY - Amsterdam

ER -

Antiobesity functional leads and targets for drug development

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this